6CM
MBIO icon

683 Capital Management’s Mustang Bio MBIO Stock Holding History

683 Capital Management’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-613
Closed -$1.74M – 214
2020
Q4 		$1.74M Hold
613
– – 0.08% 102
2020
Q3 		$1.45M Hold
613
– – 0.11% 90
2020
Q2 		$1.46M Hold
613
– – 0.12% 88
2020
Q1 		$1.23M Hold
613
– – 0.14% 84
2019
Q4 		$1.88M Sell
613
-220
-26% -$504K 0.21% 61
2019
Q3 		$2.04M Hold
833
– – 0.23% 63
2019
Q2 		$2.3M Buy
+833
New +$2.38M 0.21% 79

Other funds holding MBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's MBIO Position: Q1 2021 in Review

683 Capital Management sold out of Mustang Bio (MBIO) in Q1 2021, closing a stake of 613 shares — an estimated $1.74M sold.

683 Capital Management first reported a position in MBIO in Q2 2019 and held it in 7 quarters. The position peaked at $2.3M in Q2 2019. 95 funds tracked by Wall St. Rank hold MBIO as of Q1 2021.

  • 683 Capital Management reported no remaining Mustang Bio position as of Q1 2021 after selling out during the quarter.
  • 683 Capital Management sold 613 Mustang Bio shares in Q1 2021, an estimated $1.74M.
  • 683 Capital Management first reported a position in Mustang Bio in Q2 2019 and held it in 7 quarters.
  • 683 Capital Management's Mustang Bio position peaked at $2.3M in Q2 2019.
  • 95 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.